Skip to main content

Table 1 Baseline characteristics

From: Circulating levels of mitochondrial uncoupling protein 2, but not prohibitin, are lower in humans with type 2 diabetes and correlate with brachial artery flow-mediated dilation

 Total study population (N = 107)Healthy controls (N = 52)Type 2 DM (N = 55)P-value T2DM vs. control
Age (years)51 ± 1046 ± 956 ± 8< 0.001
Sex (% women)55.558.255.80.80
Race0.58
 Caucasian (%)82.281.882.7 
 African American (%)14.011.715.4 
 Other (%)0.91.81.9 
 Not reported (%)2.83.61 
Hispanic (%)1.93.700.50
Body mass index (kg/m2)31.9 ± 8.028.3 ± 6.235.7 ± 8.0< 0.001
Systolic blood pressure (mmHg)126 ± 17120 ± 2133 ± 12< 0.001
Diastolic blood pressure (mmHg)72 ± 1072 ± 172 ± 10.85
Heart rate (beats/min)a67 ± 1165 ± 169 ± 10.018
Total cholesterol (mg/dL)179 ± 39190 ± 40167 ± 350.002
LDL cholesterol (mg/dL)102 ± 35115 ± 3488 ± 33< 0.001
HDL cholesterol (mg/dL)53 ± 1555 ± 1650 ± 140.10
Triglycerides (mg/dL)127 ± 79101 ± 58154 ± 90< 0.001
Glucose (mg/dL)104 ± 3882 ± 10127 ± 44< 0.001
Aspirin (% use)21.51.940< 0.01
Ace inhibitors/ARBs (% use)32.7063.6< 0.01
HMG CoA reductase inhibitors (% use)26.1050.9< 0.01
β-blockers (% use)9.3018.2< 0.01
Calcium channel blockers (% use)9.3018.2< 0.01
Metformin (% use)39.3080.7< 0.01
Sulfonylureas (% use)14.0028.8< 0.01
Thiazolidinediones (% use)1.903.9< 0.01
DPP4 inhibitors (% use)0.901.9NA
SGLT2 inhibitors (% use)000NA
GLP-1 agonists (% use)000NA
Insulin (% use)0.901.9NA
Prohibitin (ng/mL)13.6 ± 0.613.4 ± 0.813.9 ± 0.70.66
UCP2 (ng/mL)3.58 ± 0.274.11 ± 0.413.01 ± 0.340.045
Δψm (mV)− 181 ± 10− 177 ± 11− 185 ± 9< 0.001
  1. aN = 39 healthy controls and N = 49 T2DM subjects